Zimmer sees shares dip despite quarterly profit; Quest launches ALS genetic test;

@FierceMedDev: EU Parliament takes action: PIP breast implants: "learn the lessons of this fraud." Release  | Follow @FierceMedDev

> Zimmer Holdings ($ZMH) posted a higher quarterly profit, but investors were still disappointed about news concerning underlying markets for reconstructive implants. The company's shares fell more than 2%. Report

> Quest Diagnostics ($DGX) is launching a new genetic testing service for amyotrophic lateral sclerosis, or Lou Gehrig's disease, to help diagnose both the familiar and sporadic versions of the condition. Release

> Meanwhile, Quest found that most Americans don't follow doctor's orders when taking their prescription drugs, either not taking their pills or seeking out medication they aren't supposed to take, according to analysis of almost 76,000 urine samples. Blog

> The Malaysian government recently passed new laws that establish a formal regulatory system for medical devices, replacing the country's existing voluntary registration model. Story

> The FDA has approved Spectranetics' new advanced GlideLight Laser Sheath tool to remove cardiac leads. Release

> The Baja Medical Device Cluster along with state government and economic development organizations are hosting the region's fifth annual Medical Device Supplier Day on June 13. Release

Pharma News

 @FiercePharma: No hiving off units for incoming J&J chief Alex Gorsky. Instead: M&A in devices, emerging markets--BloombergStory | Follow @FiercePharma

> Amgen ($AMGN) is plotting a $200 million, 100-job expansion in Ireland, with a new production plant, expanded warehouse, and R&D facilities. Article

> UCB's new products Cimzia, Neupro and Vimpat grew by 50% in the first quarter, helping to make up a 17% drop in sales of Keppra, which now faces generic competition. Report

> A Bayer unit sued Watson Pharmaceuticals ($WPI) for patent infringement, saying the genericsmaker aims to sell a copycat version of its erectile dysfunction drug Staxyn. Story

Biotech News

 @FierceBiotech: Txt msg reminders swell flu vaccine uptake--gr8! Item | Follow @FierceBiotech

 @JohnCFierce: The new CEO at AZ should get a 3-5 year shot at a turnaround in R&D. That leaves Lilly's Lechleiter in the hot seat on pipeline strategies. | Follow @JohnCFierce

 @RyanMFierce: Illumina to open app store for genomics, releases iPad app. Story | Follow @RyanMFierce

 @MarkHFierce: Australia is actively promoting a new R&D tax credit beneficial for biotech research and drug development. More | Follow @MarkHFierce

> Brennan's ouster at AstraZeneca sets stage for big changes in R&D. News

> Epizyme builds epigenetics lineup with $90M Celgene score. News

> Buzz: Is Bayer looking to buy Onyx Pharma? More

Manufacturing News

> Fixing OTC production problems is a top priority for new J&J CEO. Story

> FDA, industry differ on level of track and trace needed in U.S. Article

> Amgen VP warns FDA about quashing manufacturing innovation of biosimilars. More

> Novartis remediation drags on longer than expected. Report

CRO News

> Tom Pike joins Quintiles as new CEO. Item

> INC Research to close another facility, laying off around 30. News

> Warnex repays debentures and sells analytical services division. Article

> Cetero and FDA reach resolution over the CRO's questionable reports. Story

Vaccines News

> Celebrating vaccines: World Immunization Week 2012. Commentary

> Nigeria commits to AIDS vaccine development. News

> 'Hypervirulent' salmonella could overwhelm a vaccine. More

> Shingles shot safe and well tolerated, study finds. Story

And Finally... Intense light may be useful for treating a heart attack, Colorado University researchers believe. Release